A critical review on the use of modern sophisticated hyphenated tools in the characterization of impurities and degradation products

Journal of Pharmaceutical and Biomedical Analysis

Volumn 69, Issue , 2012, Pages 148-173

  Singh, Saranjit ^a   Handa, Tarun ^a   Narayanam, Mallikarjun ^a   Sahu, Archana ^a   Junwal, Mahendra ^a   Shah, Ravi P ^a,b  

^a NATIONAL INSTITUTE OF PHARMACEUTICAL EDUCATION AND RESEARCH NIPER   (India)

^b BRISTOL MYERS SQUIBB   (United States)

Author keywords

CE MS and CE NMR; Characterization; Hyphenated tools; Impurities and degradation products; LC MS and LC NMR; Strategies

Indexed keywords

CLOPIDOGREL; DEGRADATION PRODUCT; DRUG METABOLITE; EZETIMIBE; HYDROCHLOROTHIAZIDE; LOSARTAN; OSELTAMIVIR; TETRAHYDROISOQUINOLINE; UNCLASSIFIED DRUG;

CAPILLARY ELECTROPHORESIS; DRUG DEGRADATION; DRUG DEVELOPMENT; DRUG IMPURITY; DRUG MARKETING; DRUG SYNTHESIS; GAS CHROMATOGRAPHY; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; LIQUID CHROMATOGRAPHY; LIQUID LIQUID EXTRACTION; MASS SPECTROMETRY; NUCLEAR MAGNETIC RESONANCE; PRIORITY JOURNAL; REVIEW; SPECTROSCOPY; SUPERCRITICAL FLUID CHROMATOGRAPHY; TANDEM MASS SPECTROMETRY; ULTRA PERFORMANCE LIQUID CHROMATOGRAPHY;

CHEMISTRY, PHARMACEUTICAL; CHROMATOGRAPHY, GAS; CHROMATOGRAPHY, LIQUID; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG CONTAMINATION; GAS CHROMATOGRAPHY-MASS SPECTROMETRY; HUMANS; HYDROLYSIS; MAGNETIC RESONANCE SPECTROSCOPY; MASS SPECTROMETRY; MUTAGENS; PHARMACEUTICAL PREPARATIONS; REPRODUCIBILITY OF RESULTS; SPECTROSCOPY, FOURIER TRANSFORM INFRARED; TECHNOLOGY, PHARMACEUTICAL;

EID: 84865105313     PISSN: 07317085     EISSN: 1873264X     Source Type: Journal    
DOI: 10.1016/j.jpba.2012.03.044     Document Type: Review

References (266)

1. ICH, Impurities in new drug substances Q3A (R2), in: International Conference on Harmonisation, IFPMA, Geneva (Switzerland), 2006.
2. ICH, Impurities in new drug products Q3B (R2), in: International Conference on Harmonisation, IFPMA, Geneva (Switzerland), 2006.
3. ICH, Impurities Guideline for residual solvents Q3C (R5), in: International Conference on Harmonisation, IFPMA, Geneva (Switzerland), 2011.
4. ICH, Impurities Guideline for metal impurities Q3D, in: International Conference on Harmonisation, IFPMA, Geneva (Switzerland), 2009.
5. Gross J.M. Fanconi syndrome (adult type) developing secondary to the ingestion of outdated tetracycline. Ann. Intern. Med. 1963, 58:523-528.
6. Betto P., Turchetto L., Longinotti L. Allergenic impurities in medicinal preparations containing aminopenicillin. I. Ampicillin sodium. Ann. Ist. Super. Sanitã 1989, 25:315-317.
7. Romano A., Torres M.J., Fernandez J., Vega J.M., Mayorga C., Garcia J., Blanca M. Allergic reactions to ampicillin. Studies on the specificity and selectivity in subjects with immediate reactions. Clin. Exp. Allergy 1997, 27:1425-1431.
8. McMahon A.W., Pratt R.G., Hammad T.A., Kozlowski S., Zhou E., Lu S., Kulick C.G., Mallick T., Pan G.D. Description of hypersensitivity adverse events following administration of heparin that was potentially contaminated with oversulfated chondroitin sulfate in early 2008. Pharmacoepidemiol. Drug Saf. 2010, 19:921-933.
9. Müller L., Mauthe R.J., Riley C.M., Andino M.M., Antonis D.D., Beels C., DeGeorge J., Knaep A.G.M.D., Ellison D., Fagerland J.A., Frank R., Fritschel B., Galloway S., Harpur E., Humfrey C.D.N., Jacks A.S., Jagota N., Mackinnon J., Mohan G., Ness D.K., O'Donovan M.R., Smith M.D., Vudathala G., Yotti L. A rationale for determining, testing, and controlling specific impurities in pharmaceuticals that possess potential for genotoxicity. Regul. Toxicol. Pharmacol. 2006, 44:198-211.
10. ICH, Assessment and control of DNA reactive (mutagenic) impurities in pharmaceuticals to limit potential carcinogenic risk (final concept paper) M7, in: International Conference on Harmonisation, IFPMA, Geneva (Switzerland), 2010.
11. CPMP, Assessment of the Quality of Medicinal Products Containing Existing/Known Active Substances (EMEA/CHMP/CVMP/QWP/450653/2006), Committee for Proprietary Medicinal Products, EMEA, London (UK), 2007.
12. CPMP, Guideline on Control of Impurities of Pharmacopoeial Substances: Compliance with the European Pharmacopoeia General Monograph Substances for Pharmaceutical use and General Chapter Control of Impurities in Substances for Pharmacopoeial Use (CPMP/QWP/1529/04), Committee for Proprietary Medicinal Products, EMEA, London (UK), 2004.
13. CPMP, Guideline on the Limits of Genotoxic Impurities (CPMP/SWP/5199/02 and EMEA/CHMP/QWP/251344/2006), Committee for Proprietary Medicinal Products, EMEA, London (UK), 2007.
14. CPMP, Guidelines on Specification Limits for Residues of Metal Catalysts (CPMP/SWP/QWP/4446/00 corr.), Committee for Proprietary Medicinal Products, EMEA, London (UK), 2007.
15. CPMP, Guideline on Setting Specifications for Related Impurities in Antibiotics (draft) (EMA/CHMP/CVMP/QWP/199250/2009), Committee for Proprietary Medicinal Products, EMA, London (UK), 2010.
16. US FDA, NDAs Impurities in Drug Substances, Food and Drug Administration, Silver Spring, MD (USA), 2000.
17. US FDA, ANDAs Impurities in Drug Substances (Revision 1), Food and Drug Administration, Silver Spring, MD (USA), 2009.
18. US FDA, Genotoxic and Carcinogenic Impurities in Drug Substances and Products: Recommended Approaches (draft), Food and Drug Administration, Silver Spring, MD (USA), 2008.
19. US FDA, ANDAs Impurities in Drug Products, Food and Drug Administration, Silver Spring, MD (USA), 2010.
20. TPD, Impurities in Existing Drug Substances and Products (draft), Therapeutic Products Directorate, Health Canada, Ontario (Canada), 2005.
21. TGA, Australian Regulatory Guidelines for Prescription Medicines, Appendix 18: Impurities in Active Pharmaceutical Ingredients and Finished Products, Therapeutic Goods Administration, Woden ACT (Australia), 2004.
22. Singh S. Forensic analysis of compendial articles: the tightening noose, EDQM, USPC, anticipated fallouts, GIT Lab. J. Europe 2007, 11:38-39.
23. Glipizide Monograph, in: EP, European Pharmacopoeia 6.0, 6th Ed., Council of Europe, Strasbourg (France), 2008, pp. 1977-1979.
24. Available from: (Accessed on: 19-Mar-2012). http://www.usp.org/usp-nf/pending-monographs.
25. Available from: (Accessed on: 19-Mar-2012). http://www.fda.gov/%20Safety/Recalls/EnforcementReports/default.htm.
26. Available from: (Accessed on: 19-Mar-2012). http://www.hc-sc.gc.ca/dhp-mps/compli-conform/recall-retrait/_list/index-eng.php.
27. Available from: (Accessed on: 19-Mar-2012). http://www.tga.gov.au/safety/recalls-all.htm.
28. Available from: (Accessed on: 19-Mar-2012). http://www.fda.gov/Safety/Recalls/EnforcementReports/ucm296228.htm.
29. N. Finkelstein, Reference Standard for Characterization of Rosuvastatin, Teva Pharmaceutical Industries Ltd., US 7741482, USPTO (2010).
30. R. Grahek, D., Kocjan, A., Bastarda, A., Kocijan, M. Kračun, Oxidative degradation products of atorvastatin calcium, Lek Pharmaceuticals, US 2007/0208071, USPTO (2007).
31. S. Molnar, T., Tamas, J., Hajko, B., Kosztya, B., Kosztya, A. Eisenstadt, Mycophenolate mofetil impurity, Kenyon & Kenyon LLP, US 2008/0241948, USPTO (2008).
32. ICH, The common technical document for the registration of pharmaceuticals for human use: Quality - M4Q (R1), in: International Conference on Harmonisation, IFPMA, Geneva (Switzerland), 2002.
33. CPMP, Chemistry of new active substances (CPMP/QWP/130/96), Committee for Proprietary Medicinal Products, EMEA, London (UK), 2004.
34. CPMP, Summary of requirements for active substances in the quality part of the dossier (CHMP/QWP/297/97 Rev 1 corr. and EMEA/CVMP/1069/02), Committee for Proprietary Medicinal Products, EMEA, London (UK), 2005.
35. Available from: (Accessed on: 19-Mar-2012). http://www.fda.gov/downloads/Drugs/DevelopmentApproval%20Process/HowDrugsareDevelopedandApproved/ApprovalApplications/AbbreviatedNewDrugApplicationANDAGenerics/UCM151259.pdf.
36. TPD, Draft Guidance for Industry, Quality (chemistry and manufacturing) Guidance: New Drug Submissions (NDSs) and Abbreviated New Drug Submissions (ANDSs), Therapeutic Products Directorate, Health Canada, Ontario (Canada), 2001.
37. Available from: (Accessed on: 19-Mar-2012). http://www.moh.gov.bn/pharmacyservices/download/ASEAN%20Common%20Technical%20Document%20(ACTD).pdf.
38. WHO, Guideline on submission of documentation for a multisource (generic) finished pharmaceutical product (FPP): Quality part (draft), Working document QAS/10.373 Rev.1, World Health Organisation, Geneva (Switzerland), 2011.
39. Murakami T., Fukutsu N., Kondo J., Kawasaki T., Kusu F. Application of liquid chromatography-two-dimensional nuclear magnetic resonance spectroscopy using pre-concentration column trapping and liquid chromatography-mass spectrometry for the identification of degradation products in stressed commercial amlodipine maleate tablets. J. Chromatogr. A 2008, 1181:67-76.
40. Hajikarimian Y., Yeo S., Ryan R.W., Levett P., Stoneley C., Singh P. Investigation into the formation of the genotoxic impurity ethyl besylate in the final step manufacturing process of UK-369,003-26, a novel PDE5 inhibitor. Org. Process Res. Dev. 2010, 14:1027-1031.
41. Pozniak A., Müller L., Salgo M., Jones J.K., Larson P., Tweats D. Elevated ethyl methanesulfonate (EMS) in nelfinavir mesylate (Viracept®, Roche): overview. AIDS Res. Ther. 2009, 6:1-5.
42. Pan C., Harmon F., Toscano K., Liu F., Vivilecchia R. Strategy for identification of leachables in packaged pharmaceutical liquid formulations. J. Pharm. Biomed. Anal. 2008, 46:520-527.
43. Lin M., Li M., Rustum A. Identification of an unknown extraneous contaminant in pharmaceutical product analysis. J. Pharm. Biomed. Anal. 2007, 45:747-755.
44. Available from: (Accessed on: 19-Mar-2012). http://d3.cambridgesoft.com/.
45. Görög S., Herényi B. Analysis of steroids. XXXVIII. The use of high-performance liquid chromatography with diode-array UV detection for estimating impurity profiles of steroid drugs. J. Chromatogr. A 1987, 400:177-186.
46. Identification and Determination of Impurities in Drugs 2000, Elsevier Science, Amsterdam (Netherlands). S. Görög (Ed.).
47. Slonecker P.J., Li X., Ridgway T.H., Dorsey J.G. Informational orthogonality of two-dimensional chromatographic separations. Anal. Chem. 1996, 68:682-689.
48. Saavedra L., Huidobro A.L., García A., Cabanelas J.C., González M.G., Barbas C. CE as orthogonal technique to HPLC for alprazolam degradation product identification. Electrophoresis 2006, 27:2360-2366.
49. Reilly J., Saeed M. Capillary electrochromatography as an alternative separation technique to high-performance liquid chromatography and capillary zone electrophoresis for the determination of drug related impurities in Lilly compound LY300164. J. Chromatogr. A 1998, 829:175-186.
50. Wang X., Li W., Rasmussen H.T. Orthogonal method development using hydrophilic interaction chromatography and reversed-phase high-performance liquid chromatography for the determination of pharmaceuticals and impurities. J. Chromatogr. A 2005, 1083:58-62.
51. Wang Z., Zhang H., Liu O., Donovan B. Development of an orthogonal method for mometasone furoate impurity analysis using supercritical fluid chromatography. J. Chromatogr. A 2011, 1218:2311-2319.
52. Pharmaceutical Stress Testing: Predicting Drug Degradation 2011, Informa Healthcare, London (UK). S.W. Baertschi, K.M. Alsante, R.A. Reed (Eds.).
53. Singh S., Bakshi M. Guidance on conduct of stress tests to determine inherent stability of drugs. Pharm. Tech. On-Line 2000, 24:1-14.
54. Sattanathan P., Babu J.M., Vyas K., Reddy R.B., Rajan S.T., Sudhakar P. Structural studies of impurities of risperidone by hyphenated techniques. J. Pharm. Biomed. Anal. 2006, 40:598-604.
55. Dev R.V., Babu J.M., Vyas K., Ram P.S., Ramachandra P., Sekhar N.M., Reddy D.N.M., Rao N.S. Isolation and characterization of impurities in docetaxel. J. Pharm. Biomed. Anal. 2006, 40:614-622.
56. Brenna E., Frigoli S., Fronza G., Fuganti C., Malpezzi L. Isolation and characterisation of a phenolic impurity in a commercial sample of duloxetine. J. Pharm. Biomed. Anal. 2007, 43:1573-1575.
57. Reddy G.M., Bhaskar B.V., Reddy P.P., Ashok S., Sudhakar P., Babu J.M., Vyas K., Mukkanti K. Structural identification and characterization of potential impurities of pantoprazole sodium. J. Pharm. Biomed. Anal. 2007, 45:201-210.
58. Swamy G.Y.S.K., Ravikumar K., Wadhwa L.K., Saxena R., Singh S. (2R*,3R*,6S*)-N,6-Bis(4-fluorophenyl)-2-(4-hydroxyphenyl)-3,4,5,6-tetrahydro-2H-pyran-3-carboxamide. Acta Cryst. 2005, E61:o3608-o3610.
59. Görög S. The importance and the challenges of impurity profiling in modern pharmaceutical analysis. Trends Anal. Chem. 2006, 25:755-757.
60. Alsante K.M., Hatajik T.D., Lohr L.L., Sharp T.R. Isolation and identification of process related impurities and degradation products from pharmaceutical drug candidates, Part I. Am. Pharm. Rev. 2001, 4:70-78.
61. Görög S. Chemical and analytical characterization of related organic impurities in drugs. Anal. Bioanal. Chem. 2003, 377:852-862.
62. Lohr L.L., Sharp T.R., Alsante K.M., Hatajik T.D. Isolation and identification of process related impurities and degradation products from pharmaceutical drug candidates: Part II. The role of NMR and mass spectrometry. Am. Pharm. Rev. 2001, 4:104-113.
63. Ahuja S. Assuring quality of drugs by monitoring impurities. Adv. Drug Deliv. Rev. 2007, 59:3-11.
64. Ahuja S. Overview: isolation and characterization of impurities. Sep. Sci. Technol. 2004, 5:1-25.
65. Analysis of drug impurities, R.J., Smith, M.L. Webb (Eds.), Wiley-Blackwell, Oxford (UK), 2008.
66. Balogh G., Csizér é., Ferenczy G.G., Halmos Z., Herényi B., Horváth P., Laukó A., Görög S. Estimation of impurity profiles of drugs and related materials. 12. Isolation and identification of an isomeric impurity in danazol. Pharm. Res. 1995, 12:295-298.
67. Görög S., Halmos Z., Herényi B., Georgakis A., Balogh G., Csizér E., Tuba Z. Analysis of steroids. Part 40. Isolation and identification of unusual impurities in ethynodiol diacetate. Acta Pharm. Hung. 1991, 61:77-81.
68. Halmos Z., Szántay C., Brlik J., Csehi A., Varga K., Horváth P., Kislaki M., Domány G., Nemes A., Görög S. Estimation of impurity profiles of drugs and related materials Part 15. Identification of minor impurities in cimetidine. J. Pharm. Biomed. Anal. 1996, 15:1-5.
69. Laukó A., Csehi A., Balogh G., Csizér E., Herényi B., Görög S. Analysis of steroids. Part 42. By-products of the ethynylation of 17-ketosteroids (isolation, identification and determination). Acta Pharm. Hung. 1991, 61:98-104.
70. Baertschi S.W., Dorman D.E., Occolowitz J.L., Collins M.W., Spangle L.A., Stephenson G.A., Lorenz L.J. Isolation and structure elucidation of the major degradation products of cefaclor formed under aqueous acidic conditions. J. Pharm. Sci. 1997, 86:526-539.
71. Baertschi S.W., Dorman D.E., Occolowitz J.L., Spangle L.A., Collins M.W., Wildfeuer M.E., Lorenz L.J. Isolation and structure elucidation of a novel product of the acidic degradation of cefaclor. J. Pharm. Sci. 1993, 82:622-626.
72. Dorman D.E., Lorenz L.J., Occolowitz J.L., Spangle L.A., Collins M.W., Bashore F.N., Baertschi S.W. Isolation and structure elucidation of the major degradation products of cefaclor in the solid state. J. Pharm. Sci. 1997, 86:540-549.
73. Sigvardson K.W., Adams S.P., Barnes T.B., Blom K.F., Fortunak J.M., Haas M.J., Reilly K.L., Repta A.J., Nemeth G.A. The isolation and identification of a toxic impurity in XP315 drug substance. J. Pharm. Biomed. Anal. 2002, 27:327-334.
74. Blanchard A., Lee C., Nickerson B., Lohr L.L., Jensen A.J., Alsante K.M., Sharp T.R., Santafianos D.P., Morris R., Snyder K.D. Identification of low-level degradants from low dose tablets. J. Pharm. Biomed. Anal. 2004, 36:265-275.
75. Chow J., Liu Y., Comstock K., Brandl M., Lin F., Li F., Sarma K., Alfredson T. Isolation and identification of ester impurities in RG7128, an HCV polymerase inhibitor. J. Pharm. Biomed. Anal. 2010, 53:710-716.
76. Alsante K.M., Boutros P., Couturier M.A., Friedmann R.C., Harwood J.W., Horan G.J., Jensen A.J., Liu Q., Lohr L.L., Morris R., Raggon J.W., Reid G.L., Santafianos D.P., Sharp T.R., Tucker J.L., Wilcox G.E. Pharmaceutical impurity identification: a case study using a multidisciplinary approach. J. Pharm. Sci. 2004, 93:2296-2309.
77. Fang X., Bibart R.T., Mayr S., Yin W., Harmon P.A., McCafferty J.F., Tyrrell R.J., Reed R.A. Purification and identification of an impurity in bulk hydrochlorothiazide. J. Pharm. Sci. 2001, 90:1800-1809.
78. Lee J., Park Y., Yang W., Chung H., Choi W., Inoue H., Kuwayama K., Park J. Cross-examination of liquid-liquid extraction (LLE) and solid-phase microextraction (SPME) methods for impurity profiling of methamphetamine. Forensic Sci. Int. 2012, 215:175-178.
79. S.-Zalasik M., Li W. Determination of topiramate and its degradation product in liquid oral solutions by high performance liquid chromatography with a chemiluminescent nitrogen detector. J. Pharm. Biomed. Anal. 2005, 37:529-534.
80. Pan C., Liu F., Motto M. Identification of pharmaceutical impurities in formulated dosage forms. J. Pharm. Sci. 2011, 100:1228-1259.
81. Holzgrabe U., Nap C.J., Almeling S. Control of impurities in L-aspartic acid and L-alanine by high-performance liquid chromatography coupled with a corona charged aerosol detector. J. Chromatogr. A 2010, 1217:294-301.
82. Ferreirós N., Dresen S., Alonso R.M., Weinmann W. Hydrolysis and transesterification reactions of candesartan cilexetil observed during the solid phase extraction procedure. J. Chromatogr. B 2007, 855:134-138.
83. Bochkareva N.L., Glazkov I.N., Revelsky I.A. Combination of supercritical fluid extraction and gas chromatography-mass spectrometry: determination of impurities extracted from tablet preparations of the benzodiazepine series. J. Anal. Chem. 2006, 61:1082-1089.
84. Djozan D., Jouyban A., Norouzi J. Ultrasonic assisted SPME coupled with GC and GC-MS using pencil lead as a fiber for monitoring the organic volatile impurities of ceftazidime. J. Chromatogr. Sci. 2008, 46:680-685.
85. Fliszar K., Wiggins J.M., Pignoli C.M., Martin G.P., Li Z. Analysis of organic volatile impurities in pharmaceutical excipients by static headspace capillary gas chromatography. J. Chromatogr. A 2004, 1027:83-91.
86. McClure G.L. Improved determination of organic volatile impurities in pharmaceutical materials by (USP-467) using automated static headspace GC/MS. PDA J. Pharm. Sci. Technol. 1999, 53:129-136.
87. Liu Y., Hu C.Q. Establishment of a knowledge base for identification of residual solvents in pharmaceuticals. Anal. Chim. Acta 2006, 575:246-254.
88. Pavón J.L.P., del M., Sánchez N., Pinto C.G., Laespada M.E.F., Cordero B.M. Use of mass spectrometry methods as a strategy for detection and determination of residual solvents in pharmaceutical products. Anal. Chem. 2006, 78:4901-4908.
89. Pavón J.L.P., del M., Sánchez N., Laespada M.E.F., Pinto C.G., Cordero B.M. Analysis of class 1 residual solvents in pharmaceuticals using headspace-programmed temperature vaporization-fast gas chromatography-mass spectrometry. J. Chromatogr. A 2007, 1141:123-130.
90. Bonadio F., Margot P., Delémont O., Esseiva P. Optimization of HS-SPME/GC-MS analysis and its use in the profiling of illicit ecstasy tablets (Part 1). Forensic Sci. Int. 2009, 187:73-80.
91. Cheng J.Y.K., Chan M.F., Chan T.W., Hung M.Y. Impurity profiling of ecstasy tablets seized in Hong Kong by gas chromatography-mass spectrometry. Forensic Sci. Int. 2006, 162:87-94.
92. Gimeno P., Besacier F., H.C.-Thozet, Girard J., Lamotte A. A contribution to the chemical profiling of 3,4-methylenedioxymethamphetamine (MDMA) tablets. Forensic Sci. Int. 2002, 127:1-44.
93. Alzaga R., Ryan R.W., K.T.-Worth, Lipczynski A.M., Szucs R., Sandra P. A generic approach for the determination of residues of alkylating agents in active pharmaceutical ingredients by in situ derivatization-headspace-gas chromatography-mass spectrometry. J. Pharm. Biomed. Anal. 2007, 45:472-479.
94. Chen W., Zhou P., W.-Moon K.C., Cauchon N.S. Identification of volatile degradants in formulations containing sesame oil using SPME/GC/MS. J. Pharm. Biomed. Anal. 2007, 44:450-455.
95. Dongre V.G., Karmuse P.P., Nimbalkar M.M., Singh D., Kumar A. Application of GC-EI-MS for the identification and investigation of positional isomer in primaquine, an antimalarial drug. J. Pharm. Biomed. Anal. 2005, 39:111-116.
96. Brondz I., Fialkov A.B., Amirav A. Analysis of quinocide in unprocessed primaquine diphosphate and primaquine diphosphate tablets using gas chromatography-mass spectrometry with supersonic molecular beams. J. Chromatogr. A 2009, 1216:824-829.
97. Ding L., Wang X., Yang Z., Chen Y. The use of HPLC/MS, GC/MS, NMR, UV and IR to identify a degradation product of eperisone hydrochloride in the tablets. J. Pharm. Biomed. Anal. 2008, 46:282-287.
98. Valero M., Costa S.M.B. Photodegradation of nabumetone in aqueous solutions. J. Photochem. Photobiol. A 2003, 157:93-101.
99. Görög S., Babják M., Balogh G., Brlik J., Csehi A., Dravecz F., Gazdag M., Horváth P., Laukó A., Varga K. Drug impurity profiling strategies. Talanta 1997, 44:1517-1526.
100. Horváth P., Balogh G., Brlik J., Csehi A., Dravecz F., Halmos Z., Laukó A., Rényei M., Varga K., Görög S. Estimation of impurity profiles of drugs and related materials. Part 16: identification of the side-products of the ethinylation step in the synthesis of contraceptive gestogens. J. Pharm. Biomed. Anal. 1997, 15:1343-1349.
101. Łaniewsk K., Wannman T., Hagman G. Gas chromatography with mass spectrometric, atomic emission and fourier transform infrared spectroscopic detection as complementary analytical techniques for the identification of unknown impurities in pharmaceutical analysis. J. Chromatogr. A 2003, 985:275-282.
102. Łaniewsk K., Vågerö M., Forsberg E., Forngren T., Hagman G. Complementary use of gas chromatography-mass spectrometry, gas chromatography-atomic emission detection and nuclear magnetic resonance for identification of pharmaceutically related impurities of unknown structures. J. Chromatogr. A 2004, 1027:93-102.
103. Pan C., Liu F., Ji Q., Wang W., Drinkwater D., Vivilecchia R. The use of LC/MS, GC/MS, and LC/NMR hyphenated techniques to identify a drug degradation product in pharmaceutical development. J. Pharm. Biomed. Anal. 2006, 40:581-590.
104. K. Imatani, Advances in Q-TOF LC/MS systems for pharma applications, Available from: (Accessed on: 19-Mar-2012). http://www.iptonline.com/articles/public/P30-32%20non-print.pdf.
105. Mehta S., Shah R.P., Priyadarshi R., Singh S. LC and LC-MS/TOF studies on stress degradation behaviour of candesartan cilexetil. J. Pharm. Biomed. Anal. 2010, 52:345-354.
106. Liu D.Q., Wu L., Sun M., MacGregor P.A. On-line H/D exchange LC-MS strategy for structural elucidation of pharmaceutical impurities. J. Pharm. Biomed. Anal. 2007, 44:320-329.
107. Debrauwer L., Zalko D., Bories G., Tulliez J. Electrospray ionization mass spectrometric study of N-oxidation products of clenbuterol. Rapid Commun. Mass Spectrom. 1997, 11:1089-1094.
108. 2S. J. Am. Chem. Soc. 1998, 120:10187-10193.
109. Davies N.W., Smith J.A., Molesworth P.P., Ross J.J. Hydrogen/deuterium exchange on aromatic rings during atmospheric pressure chemical ionization mass spectrometry. Rapid Commun. Mass Spectrom. 2010, 24:1105-1110.
110. Li A.C., Yu E., Ring S.C., Chovan J.P. Identification of imine or enamine drug metabolites using online hydrogen/deuterium exchange and exact mass measurements. Rapid Commun. Mass Spectrom. 2012, 26:906-914.
111. 5+ ions generated upon electron impact. Comparison of the spectra of diphenyl ether and diphenyl carbonate. J. Am. Chem. Soc. 1968, 90:2150-2155.
112. Holman S.W., Wright P., Wells N.J., Langley G.J. Evidence for site-specific intra-ionic hydrogen/deuterium exchange in the low-energy collision-induced dissociation product ion spectra of protonated small molecules generated by electrospray ionisation. J. Mass Spectrom. 2010, 45:347-357.
113. Bristow A.W.T. Accurate mass measurement for the determination of elemental formula-a tutorial. Mass Spectrom. Rev. 2006, 25:99-111.
114. Thurman E.M., Ferrer I. The isotopic mass defect: a tool for limiting molecular formulas by accurate mass. Anal. Bioanal. Chem. 2010, 397:2807-2816.
115. Körner A. Uncovering deficiencies in mass balance using HPLC with chemiluminescence nitrogen-specific detection. LCGC North America 2002, 20:364-373.
116. Nussbaum M.A., Baertschi S.W., Jansen P.J. Determination of relative UV response factors for HPLC by use of a chemiluminescent nitrogen-specific detector. J. Pharm. Biomed. Anal. 2002, 27:983-993.
117. Mehta S., Shah R.P., Singh S. Strategy for identification and characterization of small quantities of drug degradation products using LC and LC-MS: application to valsartan, a model drug. Drug Test. Anal. 2010, 2:82-90.
118. Bansal G., Singh M., Jindal K.C., Singh S. Ultravoilet-photodiode array and high-performance liquid chromatographic/mass spectrometric studies on forced degradation behavior of glibenclamide and development of a validated stability-indicating method. J. AOAC Int. 2008, 91:709-719.
119. Bhardwaj S.P., Singh S. Study of forced degradation behaviour of enalapril maleate by LC and LC-MS and development of a validated stability-indicating assay method. J. Pharm. Biomed. Anal. 2008, 46:113-120.
120. Raijada D.K., Prasad B., Paudel A., Shah R.P., Singh S. Characterization of degradation products of amorphous and polymorphic forms of clopidogrel bisulphate under solid state stress conditions. J. Pharm. Biomed. Anal. 2010, 52:332-344.
121. Shah R.P., Kumar V., Singh S. Liquid chromatography/mass spectrometric studies on atorvastatin and its stress degradation products. Rapid Commun. Mass Spectrom. 2008, 22:613-622.
122. n, LC-NMR and on-line H/D exchange mass studies. J. Pharm. Biomed. Anal. 2010, 53:755-761.
123. Modhave D.T., Handa T., Shah R.P., Singh S. Successful characterization of degradation products of drugs using LC-MS tools: application to piroxicam and meloxicam. Anal. Methods 2011, 3:2864-2872.
124. n. J. Pharm. Biomed. Anal. 2011, 56:538-545.
125. n. J. Pharm. Biomed. Anal. 2009, 49:55-63.
126. Kumar V., Malik S., Singh S. Polypill for the treatment of cardiovascular diseases Part 2. LC-MS/TOF characterization of interaction/degradation products of atenolol/lisinopril and aspirin, and mechanism of formation thereof. J. Pharm. Biomed. Anal. 2008, 48:619-628.
127. Alsante K.M., Martin L., Baertschi S.W. A stress testing benchmarking study. Pharm. Tech. 2003, 27:60-72.
128. Klick S., Muijselaar P.G., Waterval J., Eichinger T., Korn C., Gerding T.K., Debets A.J., C.S.-van de Griend, van den Beld C., Somsen G.W., de Jong G.J. Toward a generic approach for stress testing of drug substances and drug products. Pharm. Tech. 2005, 29:48-66.
129. Reynolds D.W., Facchine K.L., Mullaney J.F., Alsante K.M., Hatajik T.D., Motto M.G. Available guidance and best practices for conducting forced degradation studies. Pharm. Tech. 2002, 26:48-56.
130. Dunn D.L., Jones W.J., Dorsey E.D. Analysis of chlorobutanol in ophthalmic ointments and aqueous solutions by reverse-phase high-performance liquid chromatography. J. Pharm. Sci. 1983, 72:277-280.
131. Garg A., Solas D.W., Takahashi L.H., Cassella J.V. Forced degradation of fentanyl: identification and analysis of impurities and degradants. J. Pharm. Biomed. Anal. 2010, 53:325-334.
132. C.C. Hodges, P.M., Llyod, D., Mufson, D.D., Rogers, M.J. Wensley, Aerosol forming device for use in inhalation therapy, Alexza Pharmaceuticals Inc., CA (US), US 2011/0240022 A1, USPTO, (2011).
133. Rabinowitz J.D., Wensley M., Lloyd P., Myers D., Shen W., Lu A., Hodges C., Hale R., Mufson D., Zaffaroni A. Fast onset medications through thermally generated aerosols. J. Pharmacol. Exp. Ther. 2004, 309:769-775.
134. Bakshi M., Singh S. Development of validated stability-indicating assay methods-critical review. J. Pharm. Biomed. Anal. 2002, 28:1011-1040.
135. Nicolas E.C., Scholz T.H. Active drug substance impurity profiling: Part I. LC/UV diode array spectral matching. J. Pharm. Biomed. Anal. 1998, 16:813-824.
136. Orr J.D., Krull I.S., Swartz M.E. Validation of impurity methods, Part I. LCGC North Am. 2003, 21:626-633.
137. Orr J.D., Krull I.S., Swartz M.E. Validation of impurity methods, Part II. LCGC North Am. 2003, 21:1146-1152.
138. Rao R.N., Nagaraju V. An overview of the recent trends in development of HPLC methods for determination of impurities in drugs. J. Pharm. Biomed. Anal. 2003, 33:335-377.
139. Skibiński R. Identification of photodegradation product of amisulpride by ultra-high-pressure liquid chromatography-DAD/ESI-quadrupole time-of-flight-mass spectrometry. J. Pharm. Biomed. Anal. 2011, 56:904-910.
140. Lecoeur M., Vérones V., Vachher C., Bonte J.-P., Lebegue N., Goossens J.-F. Structural elucidation of degradation products of a benzopyridooxathiazepine under stress conditions using electrospray orbitrap mass spectrometry-Study of degradation kinetic. Eur. J. Pharm. Sci. 2012, 45:559-569.
141. Nalwade S.U., Reddy V.R., Rao D.D., Morisetti N.K. A validated stability indicating ultra performance liquid chromatography method for determination of impurities in esomeprazole magnesium gastroresistant tablets. J. Pharm. Biomed. Anal. 2012, 57:109-114.
142. Petritis K.N., Chaimbault P., Elfakir C., Dreux M. Ion-pair reversed-phase liquid chromatography for determination of polar underivatized amino acids using perfluorinated carboxylic acids as ion pairing agent. J. Chromatogr. A 1999, 833:147-155.
143. E with mass defect filtering for in vitro and in vivo metabolite identification. Rapid Commun. Mass Spectrom. 2007, 21:1485-1496.
144. E and a semi-automated software for structural elucidation. Rapid Commun. Mass Spectrom. 2010, 24:3127-3138.
145. Giancotti V., Medana C., Aigotti R., Pazzi M., Baiocchi C. LC-high-resolution multiple stage spectrometric analysis of diuretic compounds: unusual mass fragmentation pathways. J. Pharm. Biomed. Anal. 2008, 48:462-466.
146. Wu L., Liu D.Q., Vogt F.G., Kord A.S. Gas-phase derivatization via the meerwein reaction for selective and sensitive LC-MS analysis of epoxides in active pharmaceutical ingredients. J. Pharm. Biomed. Anal. 2011, 56:1106-1111.
147. Webb K., Bristow T., Sargent M., Stein B. Methodology for Accurate Mass Measurement of Small Molecules Best Practice Guide 2004, LGC, Limited, Teddington (UK) and EPSRC National Mass Spectrometry Centre, Swansea (UK).
148. Available from: (Accessed on: 20-Mar-2012). http://www.wsearch.com.au/Tools/elemental_composition_calculator.htm.
149. Felix T., Reyzer M., Brodbelt J. Hydrogen/deuterium exchange of nucleoside analogs in a quadrupole ion trap mass spectrometer. Int. J. Mass Spectrom. 1999, 190-191:161-170.
150. Holčapek M., Jirásko R., Lísa M. Basic rules for the interpretation of atmospheric pressure ionization mass spectra of small molecules. J. Chromatogr. A 2010, 1217:3908-3921.
151. Rao R.N., Maurya P.K., Raju A.N. Isolation and characterization of a potential process related impurity of phenazopyridine HCl by preparative HPLC followed by MS-MS and 2D-NMR spectroscopy. J. Pharm. Biomed. Anal. 2009, 49:1287-1291.
152. Zhao Z., Wang Q., Tsai E.W., Qin X.-Z., Ip D. Identification of losartan degradates in stressed tablets by LC-MS and LC-MS/MS. J. Pharm. Biomed. Anal. 1999, 20:129-136.
153. Shah R.P., Sahu A., Singh S. Identification and characterization of geometrical isomeric photo degradation product of eprosartan using LC-MS and LC-NMR. Eur. J. Chem. 2011, 2:152-157.
154. Rao R.N., Vali R.M., Ramachandra B., Raju S.S. Separation and characterization of forced degradation products of abacavir sulphate by LC-MS/MS. J. Pharm. Biomed. Anal. 2011, 54:279-285.
155. Gonsalves A.R., Pineiro M., Martins J.M., Barata P.A., Meezes J.C. Identification of alprazolam and its degradation products using LC-MS-MS. ARKIVOC (v) 2010, 128-141.
156. n and accurate mass determination by ESI TOF. J. Am. Soc. Mass Spectrom. 2005, 16:1670-1676.
157. Lu C.-Y., Feng C.-H. Identification of dimer impurities in ampicillin and amoxicillin by capillary LC and tandem mass spectrometry. J. Sep. Sci. 2007, 30:329-332.
158. 2 surface by high-performance liquid chromatography/high-resolution mass spectrometry. Rapid Commun. Mass Spectrom. 2008, 22:301-313.
159. Mornar A., Damić M., Nigović B. Separation, characterization, and quantification of atorvastatin and related impurities by liquid chromatography-electrospray ionization mass spectrometry. Anal. Lett. 2010, 43:2859-2871.
160. Berendsen B.J.A., Essers M.L., Mulder P.P.J., van Bruchem G.D., Lommen A., van Overbeek W.M., Stolker L.(A.)A.M. Newly identified degradation products of ceftiofur and cephapirin impact the analytical approach for quantitative analysis of kidney. J. Chromatogr. A 2009, 1216:8177-8186.
161. Bardsley B., Barry S.J., Drozdz M.A., Hancock S.A., Okafo G.N., Szafran M.M. Formation and identification of a degradant in chlorproguanil-dapsone-artesunate (Dacart™) tablets. J. Pharm. Biomed. Anal. 2011, 54:610-613.
162. Fiori J., Grassigli G., Filippi P., Gotti R., Cavrini V. HPLC-DAD and LC-ESI-MS analysis of doxycycline and related impurities in doxipan mix, a medicated premix for incorporation in medicated feedstuff. J. Pharm. Biomed. Anal. 2005, 37:979-985.
163. Bansal G., Singh M., Jindal K.C., Singh S. LC-UV-PDA and LC-MS studies to characterize degradation products of glimepiride. J. Pharm. Biomed. Anal. 2008, 48:788-795.
164. den Brok M.W.J., Nuijen B., Hillebrand M.J.X., Lutz C., Opitz H.-G., Beijnen J.H. LC-UV method development and validation for the investigational anticancer agent imexon and identification of its degradation products. J. Pharm. Biomed. Anal. 2005, 38:686-694.
165. n, LC/TOF MS and on-line H/D exchange MS. J. Pharm. Biomed. Anal. 2012, 57:99-103.
166. 1H NMR methods for the identification of photocatalytic degradation products of iodosulfuron. Anal. Chem. 2006, 78:2957-2966.
167. Fiori J., Gotti R., Bertucci C., Cavrini V. Investigation on the photochemical stability of lercanidipine and its determination in tablets by HPLC-UV and LC-ESI-MS/MS. J. Pharm. Biomed. Anal. 2006, 41:176-181.
168. Murakami T., Kawasaki T., Takemura A., Fukutsu N., Kishi N., Kusu F. Identification of degradation products in loxoprofen sodium adhesive tapes by liquid chromatography-mass spectrometry and dynamic pressurized liquid extraction-solid-phase extraction coupled to liquid chromatography-nuclear magnetic resonance spectroscopy. J. Chromatogr. A 2008, 1208:164-174.
169. n studies for the identification and characterization of degradation products of nelfinavir mesylate. J. Pharm. Biomed. Anal. 2011, 55:435-445.
170. Qiu F., Pennino S., Busacca C.A., Norwood D.L. Identification of a process impurity formed during synthesis of a nevirapine analogue HIV NNRT inhibitor using LC/MS and forced degradation studies. J. Pharm. Biomed. Anal. 2009, 49:733-738.
171. Calza P., Medana C., Carbone F., Giancotti V., Baiocchi C. Characterization of intermediate compounds formed upon photoinduced degradation of quinolones by high-performance liquid chromatography/high-resolution multiple-stage mass spectrometry. Rapid Commun. Mass Spectrom. 2008, 22:1533-1552.
172. Liu Z.-Y., Zhang H.-H., Chen X.-J., Zhou X.-N., Wan L., Sun Z.-L. Structural elucidation of degradation products of olaquindox under stressed conditions by accurate mass measurements using electrospray ionization hybrid ion trap/time-of-flight mass spectrometry. Int. J. Mass Spectrom. 2011, 303:90-96.
173. Gratz S.R., Gamble B.M., Flurer R.A. Accurate mass measurement using fourier transform ion cyclotron resonance mass spectrometry for structure elucidation of designer drug analogs of tadalafil, vardenafil and sildenafil in herbal and pharmaceutical matrices. Rapid Commun. Mass Spectrom. 2006, 20:2317-2327.
174. Wang J., Krishnamoorthi V., Wang E., Yang C., Baptista D., Wu X., Liu M., Gardner M., Elkins P., Hines J., Liu P. LC/MS characterization of impurities and degradation products of a potent antitumor peptidic dimer, CU201. J. Pharm. Biomed. Anal. 2010, 51:824-833.
175. n experiments: development of a validated specific stability-indicating LC-MS method. J. Pharm. Biomed. Anal. 2011, 56:560-568.
176. Novak T.J., Grinberg N., Hartman B., Marcinko S., DiMichele L., Mao B. LCMS using a hybrid quadrupole time of flight mass spectrometer for impurity identification during process chemical development of a novel integrase inhibitor. J. Pharm. Biomed. Anal. 2010, 51:78-83.
177. Rao R.N., Ramachandra B., Vali R.M., Raju S.S. LC-MS/MS studies of ritonavir and its forced degradation products. J. Pharm. Biomed. Anal. 2010, 53:833-842.
178. n studies for the separation, identification and characterization of degradation products of ritonavir. Anal. Methods 2011, 3:1674-1681.
179. n analysis in conjunction with mechanism-based stress studies: identification of asarinin, an impurity from sesame oil in an animal health product. J. Pharm. Biomed. Anal. 2009, 50:1015-1021.
180. Chen Y.W., Liu Y., Novak T., Frey L., Campos K., Klapars A., C.-yi Chen, Phenix B. Identification and structural elucidation of process impurities generated in the end-game synthesis of taranabant (MK-0364) via cyanuric chloride. J. Pharm. Biomed. Anal. 2009, 49:702-710.
181. Schneider A., Wessjohann L.A. Comparison of impurity profiles of orlistat pharmaceutical products using HPLC tandem mass spectrometry. J. Pharm. Biomed. Anal. 2010, 53:767-772.
182. Pasáková I., Kovaříková P., Kučera R., KlimeŠ J., Sochor J., Hrabálek A. Development and validation of an LC-ESI-MS ion-trap method for analysis of impurities in transkarbam 12, a novel transdermal accelerant. Chromatographia 2009, 69:977-983.
183. RoŠkar R., Simončič Z., Gartner A., Kmetec V. Stability of new potential ACE inhibitor in the aqueous solutions of different pH. J. Pharm. Biomed. Anal. 2009, 49:295-303.
184. Dongre V.G., Ghugare P.D., Karmuse P., Singh D., Jadhav A., Kumar A. Identification and characterization of process related impurities in chloroquine and hydroxychloroquine by LC/IT/MS, LC/TOF/MS and NMR. J. Pharm. Biomed. Anal. 2009, 49:873-879.
185. Prasad B., Garg A., Takwani H., Singh S. Metabolite identification by liquid chromatography-mass spectrometry. Trends Anal. Chem. 2011, 30:360-387.
186. Sysoev A., Adamov A., Viidanoja J., Ketola R.A., Kostiainen R., Kotiaho T. Development of an ion mobility spectrometer for use in an atmospheric pressure ionization ion mobility spectrometer/mass spectrometer instrument for fast screening analysis. Rapid Commun. Mass Spectrom. 2004, 18:3131-3139.
187. Wu C., Siems W.F., Asbury G.R., Hill H.H. Electrospray ionization high-resolution ion mobility spectrometry-mass spectrometry. Anal. Chem. 1998, 70:4929-4938.
188. Iacob R.E., Murphy J.P., Engen J.R. Ion mobility adds an additional dimension to mass spectrometric analysis of solution-phase hydrogen/deuterium exchange. Rapid Commun. Mass Spectrom. 2008, 22:2898-2904.
189. Cuyckens F., Wassvik C., R.J.M.-Smith, Tresadern G., Campuzano I., Claereboudt J. Product ion mobility as a promising tool for assignment of positional isomers of drug metabolites. Rapid Commun. Mass Spectrom. 2011, 25:3497-3503.
190. Dwivedi P., Wu C., Matz L.M., Clowers B.H., Siems W.F., Hill H.H. Gas-phase chiral separations by ion mobility spectrometry. Anal. Chem. 2006, 78:8200-8206.
191. Cai J., Henion J. Capillary electrophoresis-mass spectrometry. J. Chromatogr. A 1995, 703:667-692.
192. Hommerson P., Khan A.M., Bristow T., Harrison M.W., de Jong G.J., Somsen G.W. Drug impurity profiling by capillary electrophoresis/mass spectrometry using various ionization techniques. Rapid Commun. Mass Spectrom. 2009, 23:2878-2884.
193. Vassort A., Barrett D.A., Shaw P.N., Ferguson P.D., Szücs R. A generic approach to the impurity profiling of drugs using standardised and independent capillary zone electrophoresis methods coupled to electrospray ionisation mass spectrometry. Electrophoresis 2005, 26:1712-1723.
194. Vassort A., Shaw P.N., Ferguson P.D., Szücs R., Barrett D.A. Comparison of CZE, open-tubular CEC and non-aqueous CE coupled to electrospray MS for impurity profiling of drugs. Electrophoresis 2008, 29:3563-3574.
195. Palmer M.E., Clench M.R., Tetler L.W., Little D.R. Exact mass determination of narrow electrophoretic peaks using an orthogonal acceleration time-of-flight mass spectrometer. Rapid Commun. Mass Spectrom. 1999, 13:256-263.
196. Palmer M.E., Tetler L.W., Wilson I.D. Hydrogen/deuterium exchange using a coaxial sheath-flow interface for capillary electrophoresis/mass spectrometry. Rapid Commun. Mass Spectrom. 2000, 14:808-817.
197. van Wijk A.M., Muijselaar P.G., Stegman K., de Jong G.J. Capillary electrophoresis-mass spectrometry for impurity profiling of basic pharmaceuticals using non-volatile background electrolytes. J. Chromatogr. A 2007, 1159:175-184.
198. Cherkaoui S., Veuthey J.L. Nonaqueous capillary electrophoresis-electrospray-mass spectrometry for the analysis of fluoxetine and its related compounds. Electrophoresis 2002, 23:442-448.
199. Li X.-F., Carter S.J., Dovichi N.J. Non-aqueous capillary electrophoresis of tamoxifen and its acid hydrolysis products. J. Chromatogr. A 2000, 895:81-85.
200. Stubberud K., Callmer K., Westerlund D. Partial filling-micellar electrokinetic chromatography optimization studies of ibuprofen, codeine and degradation products, and coupling to mass spectrometry: Part II. Electrophoresis 2003, 24:1008-1015.
201. Stubberud K., Forsberg A., Callmer K., Westerlund D. Partial filling micellar electrokinetic chromatography optimization studies of ibuprofen, codeine and degradation products, and coupling to mass spectrometry. Electrophoresis 2002, 23:572-577.
202. Yang L., Harrata A.K., Lee C.S. On-line micellar electrokinetic chromatography-electrospray ionization mass spectrometry using anodically migrating micelles. Anal. Chem. 1997, 69:1820-1826.
203. Petersson P., M.J.-Karlsson, Stålebro M. Direct coupling of micellar electrokinetic chromatography to mass spectrometry using a volatile buffer system based on perfluorooctanoic acid and ammonia. Electrophoresis 2003, 24:999-1007.
204. Ozaki H., Terabe S., Ichihara A. Micellar electrokinetic chromatography using high-molecular surfactants use of butyl acrylate-butyl methacrylate-methacrylic acid copolymers sodium salts as pseudo-stationary phases. J. Chromatogr. A 1994, 680:117-123.
205. Mol R., Kragt E., Jimidar I., de Jong G.J., Somsen G.W. Micellar electrokinetic chromatography-electrospray ionization mass spectrometry for the identification of drug impurities. J. Chromatogr. B 2006, 843:283-288.
206. Mol R., de Jong G.J., Somsen G.W. Cyclodextrin-based nonaqueous electrokinetic chromatography with UV and mass spectrometric detection: application to the impurity profiling of amiodarone. Electrophoresis 2008, 29:3575-3581.
207. Vetterlein K., Bergmann U., Büche K., Walker M., Lehmann J., Linscheid M.W., Scriba G.K.E., Professor M.H. Comprehensive profiling of the complex dendrimeric contrast agent gadomer using a combined approach of CE, MS, and CE-MS. Electrophoresis 2007, 28:3088-3099.
208. Visky D., Jimidar I., Ael W.V., Vennekens T., Redlich D., Smet M.D. Capillary electrophoresis-mass spectrometry in impurity profiling of pharmaceutical products. Electrophoresis 2005, 26:1541-1549.
209. C.-Puyana M., G.-Ruiz C., Cifuentes A., Crego A.L., Marina M.L. Identification and quantitation of cis-ketoconazole impurity by capillary zone electrophoresis-mass spectrometry. J. Chromatogr. A 2006, 1114:170-177.
210. S.-Hernández L., G.-Ruiz C., Crego A.L., Marina M.L. Sensitive determination of D-carnitine as enantiomeric impurity of levo-carnitine in pharmaceutical formulations by capillary electrophoresis-tandem mass spectrometry. J. Pharm. Biomed. Anal. 2010, 53:1217-1223.
211. Carvalho A.Z., E.-Attug M.N., Zayed S.E., Hove E.V., Duppen J.V., Hoogmartens J., Schepdael A.V. Micellar electrokinetic chromatography method development for determination of impurities in ritonavir. J. Pharm. Biomed. Anal. 2010, 53:1210-1216.
212. Okafo G., Tolson D., Monte S., Marchbank J. Analysis of process impurities in the basic drug SB-253149 using capillary electrophoresis and on-line mass spectrometric detection. Rapid Commun. Mass Spectrom. 2000, 14:2320-2327.
213. Brondz I., Ekeberg D., Bell D.S., Annino A.R., Hustad J.A., Svendsen R., Vlachos V., Oakley P., Langley G.J., Mohini T., Amaury C.-G., Mikhalitsyn F. Nature of the main contaminant in the drug primaquine diphosphate: SFC and SFC-MS methods of analysis. J. Pharm. Biomed. Anal. 2007, 43:937-944.
214. Watanabe N., Niki E. Direct-coupling of FT-NMR to high performance liquid chromatography. Proc. Jpn. Acad. Ser. B Phys. Biol. Sci. 1978, 54:194-199.
215. Colson K.L. Ultracool NMR technology. Mod. Drug Discov. 2003, 47-51.
216. Kovacs H., Moskau D., Spraul M. Cryogenically cooled probes-a leap in NMR technology. Prog. Nucl. Magn. Reson. Spectrosc. 2005, 46:131-155.
217. Webb A.G. Microcoil nuclear magnetic resonance spectroscopy. J. Pharm. Biomed. Anal. 2005, 38:892-903.
218. Mukhopadhyay R. Liquid NMR probes: oh so many choices. Anal. Chem. 2007, 79:7959-7963.
219. Smallcombe S.H., Patt S.L., Keifer P.A. WET solvent suppression and its applications to LC-NMR and high-resolution NMR spectroscopy. J. Magn. Reson. A 1995, 117:295-303.
220. Neuhaus D., Ismail I.M., Chung C.-W. FLIPSY-A new solvent-suppression sequence for nonexchanging solutes offering improved integral accuracy relative to 1D NOESY. J. Magn. Reson. A 1996, 118:256-263.
221. Peng S.X., Borah B., Dobson R.L.M., Liu Y.D., Pikul S. Application of LC-NMR and LC-MS to the identification of degradation products of a protease inhibitor in dosage formulations. J. Pharm. Biomed. Anal. 1999, 20:75-89.
222. Dachtler M., Glaser T., Kohler K., Albert K. Combined HPLC-MS and HPLC-NMR on-line coupling for the separation and determination of lutein and zeaxanthin stereoisomers in spinach and in retina. Anal. Chem. 2001, 73:667-674.
223. Lindon J.C., Nicholson J.K., Wilson I.D. Directly coupled HPLC-NMR and HPLC-NMR-MS in pharmaceutical research and development. J. Chromatogr. B 2000, 748:233-258.
224. M.-H. Wann, 20 Application of LC-NMR in pharmaceutical analysis, Sep. Sci. Technol. 6 (2005) 569-579.
225. Mistry N., Ismail I.M., Smith M.S., Nicholson J.K., Lindon J.C. Characterization of impurities in bulk drug batches of fluticasone propionate using directly coupled HPLC-NMR spectroscopy and HPLC-MS. J. Pharm. Biomed. Anal. 1997, 16:697-705.
226. Segmuller B.E., Armstrong B.L., Dunphy R., Oyler A.R. Identification of autoxidation and photodegradation products of ethynylestradiol by on-line HPLC-NMR and HPLC-MS. J. Pharm. Biomed. Anal. 2000, 23:927-937.
227. Junwal M., Sahu A., Handa T., Shah R.P., Singh S. ICH guidance in practice: degradation behaviour of oseltamivir phosphate under stress conditions. J. Pharm. Biomed. Anal. 2012, 62:48-60.
228. Vogt F.G., Wu L., Olsen M.A., Clark W.M. A spectroscopic and computational study of an electrocyclized photo-degradation product of 6-(2-(5-chloro-2-(2,4-difluorobenzyloxy)phenyl)cyclopent-1-enyl)picolinic acid. J. Mol. Struct. 2010, 984:246-261.
229. Murakami T., Konno H., Fukutsu N., Onodera M., Kawasaki T., Kusu F. Identification of a degradation product in stressed tablets of olmesartan medoxomil by the complementary use of HPLC hyphenated techniques. J. Pharm. Biomed. Anal. 2008, 47:553-559.
230. Novak P., TepeŠ P., Cindrić M., IlijaŠ M., Dragojević S., Mihaljević K. Combined use of liquid chromatography-nuclear magnetic resonance spectroscopy and liquid chromatography-mass spectrometry for the characterization of an acarbose degradation product. J. Chromatogr. A 2004, 1033:299-303.
231. Fukutsu N., Kawasaki T., Saito K., Nakazawa H. Application of high-performance liquid chromatography hyphenated techniques for identification of degradation products of cefpodoxime proxetil. J. Chromatogr. A 2006, 1129:153-159.
232. Roberts J.K., Smith R.J. Use of liquid chromatography-nuclear magnetic resonance spectroscopy for the identification of impurities in drug substances. J. Chromatogr. A 1994, 677:385-389.
233. Novak P., TepeŠ P., IlijaŠ M., Fistrić I., BratoŠ I., Avdagić A., HamerŠak Z., Marković V.G., Dumić M. LC-NMR and LC-MS identification of an impurity in a novel antifungal drug icofungipen. J. Pharm. Biomed. Anal. 2009, 50:68-72.
234. Larsen J., Staerk D., Cornett C., Hansen S.H., Jaroszewski J.W. Identification of reaction products between drug substances and excipients by HPLC-SPE-NMR: ester and amide formation between citric acid and 5-aminosalicylic acid. J. Pharm. Biomed. Anal. 2009, 49:839-842.
235. n, on-line H/D exchange and LC-NMR. J. Pharm. Biomed. Anal. 2010, 51:1037-1046.
236. Provera S., Rovatti L., Turco L., Mozzo S., Spezzaferri A., Bacchi S., Ribecai A., Guelfi S., Mingardi A., Marchioro C., Papini D. A multi-technique approach using LC-NMR, LC-MS, semi-preparative HPLC, HR-NMR and HR-MS for the isolation and characterization of low-level unknown impurities in GW876008, a novel corticotropin-release factor 1 antagonist. J. Pharm. Biomed. Anal. 2010, 53:517-525.
237. Potts B.C.M., Albizati K.F., Johnson M.O., James J.P. Application of LC-NMR to the identification of bulk drug impurities in GART inhibitor AG2034. Magn. Reson. Chem. 1999, 37:393-400.
238. Novak P., TepeŠ P., Fistrić I., BratoŠ I., Gabelica V. The application of LC-NMR and LC-MS for the separation and rapid structure elucidation of an unknown impurity in 5-aminosalicylic acid. J. Pharm. Biomed. Anal. 2006, 40:1268-1272.
239. Dev R.V., Kiran G.S.U., Subbaiah B.V., Babu B.S., Babu J.M., Dubey P.K., Vyas K. Identification of degradation products in stressed tablets of rabeprazole sodium by HPLC-hyphenated techniques. Magn. Reson. Chem. 2009, 47:443-448.
240. Feng W., Liu H., Chen G., Malchow R., Bennet F., Lin E., Pramanik B., Chan T.-M. Structural characterization of the oxidative degradation products of an antifungal agent SCH 56592 by LC-NMR and LC-MS. J. Pharm. Biomed. Anal. 2001, 25:545-557.
241. McCrossen S.D., Bryant D.K., Cook B.R., Richards J.J. Comparison of LC detection methods in the investigation of non-UV detectable organic impurities in a drug substance. J. Pharm. Biomed. Anal. 1998, 17:455-471.
242. Wu L., Hong T.Y., Yogt F.G. Structural analysis of photo-degradation in thiazole containing compounds by LC-MS/MS and NMR. J. Pharm. Biomed. Anal. 2007, 44:763-772.
243. Elipe M.V.S. LC/NMR and LC/MS/NMR. Encyclopedia of chromatography 2010, CRC Press. 3rd Edn. Jack Cazes (Ed.).
244. Provera S., Martini L., Guercio G., Turco L., Costa L., Marchioro C. Application of LC-NMR and HR-NMR to the characterization of biphenyl impurities in the synthetic route development for vestipitant, a novel NK1 antagonist. J. Pharm. Biomed. Anal. 2010, 53:389-395.
245. Jayawickrama D.A., Sweedler J.V. Hyphenation of capillary separations with nuclear magnetic resonance spectroscopy. J. Chromatogr. A 2003, 1000:819-840.
246. Lacey M.E., Subramanian R., Olson D.L., Webb A.G., Sweedler J.V. High-resolution NMR spectroscopy of sample volumes from 1nL to 10μL. Chem. Rev. 1999, 99:3133-3152.
247. Schroeder F.C., Gronquist M. Extending the scope of NMR spectroscopy with microcoil probes. Angew. Chem. Int. Ed. 2006, 45:7122-7131.
248. 1H NMR: application to online detection in capillary electrophoresis. J. Am. Chem. Soc. 1994, 116:7929-7930.
249. 1H-NMR spectroscopy on the nanoliter scale for static and online measurements. Anal. Chem. 1994, 66:3849-3857.
250. Webb A.G. Radiofrequency microcoils in magnetic resonance. Prog. Nucl. Magn. Reson. Spectrosc. 1997, 31:1-42.
251. Hoult D.I., Richards R.E. The signal-to-noise ratio of the nuclear magnetic resonance experiment. J. Magn. Reson. 1976, 24:71-85.
252. 1H NMR detection using periodic stopped-flow capillary electrophoresis. Anal. Chem. 1999, 71:3070-3076.
253. Li Y., Lacey M.E., Sweedler J.V., Webb A.G. Spectral restoration from low signal-to-noise, distorted NMR signals: application to hyphenated capillary electrophoresis-NMR. J. Magn. Reson. 2003, 162:133-140.
254. Wolters A.M., Jayawickrama D.A., Webb A.G., Sweedler J.V. NMR detection with multiple solenoidal microcoils for continuous-flow capillary electrophoresis. Anal. Chem. 2002, 74:5550-5555.
255. Diekmann J., Adams K.L., Klunder G.L., Evans L., Steele P., Vogt C., Herberg J.L. Portable microcoil NMR detection coupled to capillary electrophoresis. Anal. Chem. 2011, 83:1328-1335.
256. Wolters A.M., Jayawickrama D.A., Larive C.K., Sweedler J.V. Capillary isotachophoresis/NMR: extension to trace impurity analysis and improved instrumental coupling. Anal. Chem. 2002, 74:2306-2313.
257. Eldridge S.L., Almeida V.K., Korir A.K., Larive C.K. Separation and analysis of trace degradants in a pharmaceutical formulation using on-line capillary isotachophoresis-NMR. Anal. Chem. 2007, 79:8446-8453.
258. Somsen G.W., Gooijer C., Brinkman U.A.T. Liquid chromatography-fourier-transform infrared spectrometry. J. Chromatogr. A 1999, 856:213-242.
259. Somsen G.W., Gooijer C., Brinkman U.A.T., Velthorst N.H., Visser T. Coupling of LC and FT-IR: impurity profiling of testosterone undecanoate. Appl. Spectrosc. 1992, 46:1514-1519.
260. Somsen G.W., Jagt I., Gooijer C., Velthorst N.H., Brinkman U.A.T., Visser T. Identification of herbicides in river water using on-line trace enrichment combined with column liquid chromatography-fourier-transform infrared spectrometry. J. Chromatogr. A 1996, 756:145-157.
261. Borges N.C.C., Mendes G.D., Borges A., de Oliveira S.E., B.-Astigarraga R.E., Nucci G.D. Ticlopidine quantification in human plasma by high-performance liquid chromatography coupled to electrospray tandem mass spectrometry. Application to bioequivalence study. J.Mass Spectrom. 2004, 39:1562-1569.
262. Danikiewicz W., Świst M. JMS, Letters. J. Mass Spectrom. 2007, 42:405-406.
263. Mass Spectrometry of Heterocyclic Compounds 1985, John Wiley, New York. Q.N. Porter (Ed.).
264. Gajjar A.K., Shah V.D. Isolation and structure elucidation of major alkaline degradant of ezetimibe. J. Pharm. Biomed. Anal. 2011, 55:225-229.
265. Barhate C.R., Mohanraj K. What is the degradation product of ezetimibe?. J. Pharm. Biomed. Anal. 2011, 55:1237-1238.
266. Sánta Z., Kóti J., Szoke K., Vukics K., Szántay C. Structure of the major degradant of ezetimibe. J. Pharm. Biomed. Anal. 2012, 58:125-129.